American Healthcare REIT earnings release, May 7, 2026

American Healthcare REIT, Inc. (AHR) · Form 8-K, Item 2.02 · Filed · SEC filing

Press Release

American Healthcare REIT Announces First Quarter 2026 Results;

Increases Full Year 2026 Guidance

American Healthcare REIT, Inc. (NYSE: AHR) (the “Company,” “we,” “our,” or “AHR”) is announcing today its first quarter 2026 results and increasing full year 2026 guidance.

Key Highlights:

“Our first quarter results reflect another exceptionally strong period across our core metrics, including our ninth consecutive quarter of double-digit Same-Store NOI growth, efficient capital formation and accretive deployment, a strengthened balance sheet, and a raise to our full year 2026

Same-Store NOI growth and NFFO per share guidance,” said Jeff Hanson, Chairman, Interim Chief Executive Officer and President. “These results reflect AHR’s mission to deliver higher-quality care and superior resident and patient outcomes while serving as the most sought-after and trusted capital partner for the best operators in our industry.”

Page | 1

First Quarter 2026 Results

The Company’s Same-Store NOI growth results for the three months ended March 31, 2026 are detailed below. Same-Store NOI growth in the first quarter of 2026, compared to the same period in 2025, was led by the Company’s operating portfolio, comprised of its ISHC and SHOP segments, through disciplined revenue management and effective expense control by its regional operating partners.

Three Months Ended March 31, 2026 Relative to Three Months Ended

March 31, 2025

“Our senior housing portfolio delivered strong operating performance this quarter, with Trilogy once again distinguishing itself as a leader in the sector through the strength of its differentiated operating model,” said Gabe Willhite, the Company’s Chief Operating Officer. “The consistency and quality of Trilogy’s results underscore the durability of its approach and its ability to drive sustained superior performance. Across the broader senior housing portfolio, we were able to drive continued NOI expansion by actively managing a range of operational and pricing levers, dynamically balancing them to optimize profitability and maximize total NOI. We remain confident in our ability to build on this momentum and deliver sustained earnings growth as we continue executing on these strategies.”

Transactional Activity

During the three months ended March 31, 2026, the Company:

Subsequent to the quarter ended

March 31, 2026, the Company:

Following the Company’s completed transaction activity during the three months ended March 31, 2026, and subsequent to quarter end, the Company’s investments pipeline consists of over $650 million which includes newly awarded deals and deals in the pipeline previously disclosed in the Company’s Fourth Quarter 2025 Earnings Release that have yet to close. While the Company expects to close the deals in its investments pipeline by the end of 2026, it cannot guarantee when or if these closings will take place. Therefore, the Company is not including any additional transaction activity, including the awarded deals in its investments pipeline, in its 2026 guidance, beyond the transactions disclosed as completed.

Page | 2

Development Activity

The Company completed three and started two development projects during the three months ended March 31, 2026.The Company’s total in-process development and expansion pipeline is expected to cost approximately $173.9 million, of which $52.4 million had been funded as of March 31, 2026.

Capital Markets and Balance Sheet Activity

As of

March 31, 2026, the Company had total consolidated indebtedness of $1.53 billion and approximately $1.31 billion of total liquidity, comprised of cash and cash equivalents, undrawn capacity on its lines of credit, and expected gross proceeds from unsettled forward sale agreements, assuming full physical settlement. The Company’s

Net-Debt-to-Annualized

Adjusted EBITDA as of March 31, 2026, was 3.0x.

During the three months ended March 31, 2026, the Company entered into forward sale agreements pursuant to its ATM Program, to sell 7,028,164 shares of common stock for approximately $357.4 million in gross proceeds, assuming full physical settlement. Subsequent to quarter end, the Company entered into additional forward sale agreements pursuant to its ATM Program to sell 2,561,583 shares of common stock for approximately $123.7 million in gross proceeds, assuming full physical settlement.

During the three months ended March 31, 2026, the Company issued 3,974,731 shares of common stock to settle sales under previously discussed forward sale agreements from its ATM Program and its November 2025 equity offering for gross proceeds of approximately $191.2 million. Subsequent to quarter end, the Company issued an additional 2,755,996 shares of common stock to settle sales under forward sale agreements from its ATM Program for gross proceeds of approximately $134.0 million. As of May 7, 2026, pursuant to its ATM Program, the Company had unsettled forward sale agreements outstanding relating to 10,498,207 shares of common stock that would result in approximately $527.4 million in gross proceeds assuming full physical settlement.

Additionally, subsequent to quarter end, the Company amended its credit facility by increasing the size of the unsecured revolving credit facility portion from $600 million to $800 million, thereby increasing the total aggregate credit facility including term loan to

$1.35 billion. The revolving portion of the credit facility now matures on April 1, 2030, and may be extended for two

6-month periods, subject to certain conditions. Further, the Company may increase the aggregate incremental amount of the entire credit facility from $1.35 billion to $1.85 billion, subject to certain terms and conditions. The Company’s existing unsecured term loan facility within the credit facility in the... (truncated)e amount of $550 million remains unchanged.

“Our proactive hands-on asset management approach has led to solid financial performance at the start of 2026, allowing us to increase our Same-Store NOI growth and NFFO per diluted share guidance for the year,” said Brian Peay, the Company’s Chief Financial Officer. “Our updated Same-Store NOI growth guidance at the midpoint would suggest a third consecutive double-digit growth year for AHR. Additionally, we have supplemented that organic growth with accretive acquisitions utilizing capital we have sourced through our equity offering programs at attractive prices. With well over $1 billion available on our existing ATM program we plan to continue to utilize forward sale agreements to the extent that the stock continues to trade well, in addition to using the capacity on our line of credit, thereby de-risking the execution of new investments in our pipeline that we expect to close by the end of the year.”

Page | 3

Full Year 2026 Guidance

The Company is increasing NFFO per diluted share and Same-Store NOI growth guidance for the year ending December 31, 2026. The Company’s 2026 guidance does not assume any additional transaction or capital markets activity beyond the transactions or activity disclosed herein as completed. Guidance ranges are detailed below:

Certain of the assumptions underlying the Company’s 2026 guidance can be found within the

Non-GAAP reconciliations in this earnings release and in the appendix of the Company’s First Quarter 2026 Supplemental Financial Information (“Supplemental”). A reconciliation of net income

(loss) calculated in accordance with GAAP to NAREIT FFO and NFFO can be found within the

Non-GAAP reconciliations in this earnings release.

Non-GAAP financial measures and other terms, as used in this earnings release, are also defined and further explained in the Supplemental. The Company is unable to provide, without unreasonable effort, guidance for the most comparable GAAP financial measures of total revenues and property operating and maintenance expenses. Additionally, a reconciliation of the forward-looking non-GAAP financial measures of Same-Store NOI growth to the comparable GAAP financial measures cannot be provided without unreasonable effort because the Company is unable to reasonably predict certain items contained in the GAAP measures, including non-recurring and infrequent items that are not indicative of the Company’s ongoing operations. Such items include, but are not limited to, impairment on depreciated real estate assets, net gain or loss on sale of real estate assets, stock-based compensation, casualty loss, non-Same-Store revenue and non-Same-Store operating expenses. These items are uncertain, depend on various factors and could have a material impact on the

Company’s GAAP results for the guidance period.

Distributions

As previously announced, the Company’s Board of Directors declared a cash distribution for the quarter ended March 31, 2026 of $0.25 per share of its common stock. The first quarter distribution was paid in cash on April 17, 2026, to stockholders of record as of March 31, 2026.

Supplemental Information

The Company has disclosed supplemental information regarding its portfolio, financial position and results of operations as of, and for the three months ended, March 31, 2026, and certain other information, which is available on the Investor Relations section of the Company’s website at https://ir.americanhealthcarereit.com.

Conference Call and Webcast Information

The Company will host a webcast and conference call at 1:00 p.m. Eastern Time on May 8, 2026. During the conference call, Company executives will review first quarter 2026 results, discuss recent events and conduct a question-and-answer period.

To join via webcast, investors may use the following link: https://events.q4inc.com/attendee/173789053.

To join the live telephone conference call, please dial one of the following numbers at least five minutes prior to the start time:

United States (Local): +1 585 542 9983

United States

(Toll-Free): +1 833 461 5787

International

Dial-Ins: https://help.events.q4inc.com/eahc/international-dial-in-numbers

Meeting ID: 173789053

A digital replay of the call will be available on the Investor Relations section of the Company’s website at https://ir.americanhealthcarereit.com shortly after the conclusion of the call.

Page | 4

Financial statements

Income Statement

Three Months Ended March 31, — (In thousands, except share and per share amounts) (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenues:Resident fees and services609,767497,176
Revenues:Real estate revenue41,00743,427
Revenues:Total revenues650,774540,603
Expenses:Property operating expenses512,171432,423
Expenses:Rental expenses13,10013,643
Expenses:General and administrative17,60513,155
Expenses:Transaction, transition and restructuring costs1,9711,837
Expenses:Depreciation and amortization67,06241,114
Expenses:Total expenses611,909502,172
Interest expense:Interest expense, net-18,796-22,945
Interest expense:Gain (loss) in fair value of derivative financial instruments1,527-750
Interest expense:Loss on dispositions of real estate investments, net-359
Interest expense:Impairment of real estate investments-418-21,706
Interest expense:Income (loss) from unconsolidated entities792-1,848
Interest expense:Foreign currency (loss) gain-8191,416
Interest expense:Other income, net2,3351,525
Interest expense:Total net other expense-15,379-44,667
Interest expense:Income (loss) before income taxes23,486-6,236
Interest expense:Income tax benefit (expense)525-604
Interest expense:Net income (loss)24,011-6,840
Interest expense:Net (income) loss attributable to noncontrolling interests-29836
Interest expense:Net income (loss) attributable to controlling interest23,713-6,804
Net income (loss) per common share attributable to controlling interest:Basic0.13-0.04
Net income (loss) per common share attributable to controlling interest:Diluted0.13-0.04
Weighted average number of common shares outstanding:Basic187,319,513156,922,819
Weighted average number of common shares outstanding:Diluted187,970,438156,922,819
Weighted average number of common shares outstanding:Net income (loss)24,011-6,840
Other comprehensive (loss) income:Foreign currency translation adjustments-120176
Other comprehensive (loss) income:Total other comprehensive (loss) income-120176
Other comprehensive (loss) income:Comprehensive income (loss)23,891-6,664
Other comprehensive (loss) income:Comprehensive (income) loss attributable to noncontrolling interests-29836
Other comprehensive (loss) income:Comprehensive income (loss) attributable to controlling interest23,593-6,628

Income Statement

Three Months Ended March 31, — (In thousands, except share and per share amounts) (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net income (loss)24,011-6,840
Depreciation and amortization related to real estate — consolidated properties66,99341,015
Depreciation and amortization related to real estate — unconsolidated entities14497
Impairment of real estate investments — consolidated properties41821,706
Loss on dispositions of real estate investments, net — consolidated properties359
Net (income) loss attributable to noncontrolling interests-29836
Depreciation, amortization, impairments and net loss on dispositions — noncontrolling interests-784-892
NAREIT FFO attributable to controlling interest90,35455,881
Transaction, transition and restructuring costs1,9711,837
Amortization of above- and below-market leases330413
Amortization of closing costs — debt security investment1237
Change in deferred rent-582-672
Non-cash impact of changes to equity instruments4,8582,551
Non-cash income tax benefit-724
Capitalized interest-644-97
Loss on debt extinguishments508
(Gain) loss in fair value of derivative financial instruments-1,527750
Foreign currency loss (gain)819-1,416
Adjustments for unconsolidated entities-1
Adjustments for noncontrolling interests-51-50
Normalized FFO attributable to controlling interest94,81559,742
NAREIT FFO and Normalized FFO weighted average common share outstanding — diluted187,970,438157,428,446
NAREIT FFO per common share attributable to controlling interest — diluted0.480.35
Normalized FFO per common share attributable to controlling interest — diluted0.50.38

Income Statement

(In thousands) (Unaudited) (in thousands)

Net income24,011
Interest expense, net (including amortization of deferred financing costs and debt discount/premium)18,796
Income tax benefit-525
Depreciation and amortization (including amortization of leased assets and accretion of lease liabilities)67,506
EBITDA109,788
Income from unconsolidated entities-792
Straight line rent and amortization of above/below market leases-696
Non-cash impact of changes to equity instruments4,858
Transaction, transition and restructuring costs1,971
Amortization of closing costs — debt security investment12
Foreign currency loss819
Gain in fair value of derivative financial instruments-1,527
Impairment of real estate investments418
Adjusted EBITDA114,851

Income Statement

Three Months Ended March 31, — (In thousands) (Unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net income (loss)24,011-6,840
General and administrative17,60513,155
Transaction, transition and restructuring costs1,9711,837
Depreciation and amortization67,06241,114
Interest expense18,79622,945
(Gain) loss in fair value of derivative financial instruments-1,527750
Loss on dispositions of real estate investments, net359
Impairment of real estate investments41821,706
(Income) loss from unconsolidated entities-7921,848
Foreign currency loss (gain)819-1,416
Other income, net-2,335-1,525

Balance Sheet

March 31, 2026 — (In thousands, except share and per share amounts) (Unaudited)

March 31, 2026 – ASSETSDecember 31, 2025 – ASSETS
Real estate investments, net4,319,9114,183,419
Debt security investment, net92,30492,136
Cash and cash equivalents119,380114,836
Restricted cash37,50436,917
Accounts and other receivables, net241,594204,313
Identified intangible assets, net250,424253,236
Goodwill234,942234,942
Operating lease right-of-use assets, net130,405135,399
Other assets, net172,194171,028
Total assets5,598,6585,426,226
LIABILITIES AND EQUITYLIABILITIES AND EQUITYLIABILITIES AND EQUITY
Liabilities:Mortgage loans payable, net962,375966,925
Liabilities:Lines of credit and term loan, net549,818549,761
Liabilities:Accounts payable and accrued liabilities340,265317,742
Liabilities:Identified intangible liabilities, net1,9782,110
Liabilities:Financing obligations33,67533,902
Liabilities:Operating lease liabilities130,806135,603
Liabilities:Security deposits, prepaid rent and other liabilities58,38659,568
Liabilities:Total liabilities2,077,3032,065,611
Stockholders’ equity:Common stock, $0.01 par value per share; 700,000,000 shares authorized; 189,942,357 and 185,911,442 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1,8941,852
Stockholders’ equity:Additional paid-in capital5,065,4464,880,169
Stockholders’ equity:Accumulated deficit-1,583,441-1,559,279
Stockholders’ equity:Accumulated other comprehensive loss-2,224-2,104
Stockholders’ equity:Total stockholders’ equity3,481,6753,320,638
Stockholders’ equity:Noncontrolling interests39,68039,977
Stockholders’ equity:Total equity3,521,3553,360,615
Stockholders’ equity:Total liabilities and equity5,598,6585,426,226
Full release

Forward-Looking Statements

Certain statements contained in this press release, including statements relating to the Company’s expectations regarding its performance, interest expense savings, balance sheet, net income or loss attributable to common stockholders and per diluted share, NAREIT FFO attributable to common stockholders and per diluted share, NFFO attributable to common stockholders and per diluted share, total portfolio Same-Store NOI growth, segment-level Same-Store NOI growth, occupancy, NOI growth, revenue growth, purchases and sales of assets, development plans, and the settlement of forward sale agreements may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends for all such forward-looking statements to be covered by the applicable safe harbor provisions for forward-looking statements contained in those acts. Such forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “can,”

“expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” “possible,” “initiatives,” “focus,” “seek,”

“objective,” “goal,” “strategy,” “plan,” “potential,” “potentially,” “preparing,” “projected,” “future,” “long-term,”... (truncated)n these forward-looking statements, which speak only as of the date of this press release. Any such forward-looking statements are based on current expectations, estimates and projections about the industry and markets in which the Company operates, and beliefs of, and assumptions made by, the Company’s management and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied therein, including, without limitation, changing macroeconomic conditions, domestic legal and fiscal policies, and geopolitical conditions and other risks disclosed in the Company’s Annual Report on Form

10-K for the year ended December 31, 2025, filed on February 27,

2026, and subsequent periodic reports filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any obligation to update or revise any forward-looking statements contained in this release.

Non-GAAP

Financial Measures

The Company’s reported results are presented in accordance with GAAP. The Company also discloses the following non-GAAP financial measures: EBITDA, Adjusted EBITDA, Net

Debt-to-Annualized

Adjusted EBITDA, NAREIT FFO, NFFO, NOI and

Same-Store NOI. The Company believes these non-GAAP financial measures are useful supplemental measures of its operating performance and used by investors and analysts to compare the operating performance of the Company between periods and to other REITs or companies on a consistent basis without having to account for differences caused by unanticipated and/or incalculable items. Definitions of the non-GAAP financial measures used herein and reconciliations to the most directly comparable financial measure calculated in accordance with GAAP can be found at the end of this earnings release. See below and “Definitions” for further information regarding the Company’s non-GAAP financial measures.

EBITDA and Adjusted EBITDA

Management uses earnings before interest, taxes, depreciation and amortization (“EBITDA”) and Adjusted EBITDA to facilitate internal and external comparisons to our historical operating results and in making operating decisions. EBITDA and Adjusted EBITDA are widely used by investors, lenders, credit and equity analysts in the valuation, comparison, and investment recommendations of companies. Additionally, EBITDA and Adjusted EBITDA are utilized by our Board of Directors to evaluate management. Neither EBITDA nor Adjusted EBITDA represents net income (loss) or cash flows provided by operating activities as determined in accordance with GAAP and should not be considered as alternative measures of profitability or liquidity. Finally, the EBITDA and Adjusted EBITDA may not be comparable to similarly entitled items reported by other REITs or other companies. In addition, management uses Net

Debt-to-Annualized

Adjusted EBITDA as a measure of our ability to service our debt.

NAREIT Funds from Operations (FFO) and Normalized Funds from Operations (NFFO)

We believe that the use of FFO, which excludes the impact of real estate-related depreciation and amortization and impairments, provides a further understanding of our operating performance to investors, industry analysts and our management, and when compared year over year, reflects the impact on our operations from trends in occupancy rates, rental rates, operating costs, general and administrative expenses and interest costs, which may not be immediately apparent from net income (loss) as determined in accordance with GAAP. However, FFO

Page | 5 and NFFO should not be construed to be (i) more relevant or accurate than the current GAAP methodology in calculating net income (loss) as an indicator of our operating performance,

(ii) more relevant or accurate than GAAP cash flows from operations as an indicator of our liquidity or (iii) indicative of funds available to fund our cash needs, including our ability to make distributions to our stockholders. The method utilized to evaluate the value and performance of real estate under GAAP should be construed as a more relevant measure of operational performance and considered more prominently than the non-GAAP

FFO and NFFO measures and the adjustments to GAAP in calculating FFO and NFFO. Presentation of this information is intended to provide useful information to investors, industry analysts and management as they compare the operating performance metrics used by the

REIT industry, although it should be noted that some REITs may use different methods of calculating funds from operations and normalized funds from operations, so comparisons with such REITs may not be meaningful.

Net Operating Income (NOI)

We believe that NOI,

Cash NOI,

Pro-Rata

Cash NOI and Same-Store NOI are appropriate supplemental performance measures to reflect the performance of our operating assets because NOI, Cash NOI,

Pro-Rata

Cash NOI and Same-Store NOI exclude certain items that are not associated with the operations of the properties. We believe that NOI, Cash NOI,

Pro-Rata

Cash

NOI and Same-Store NOI are widely accepted measures of comparative operating performance in the real estate community and are useful to investors in understanding the profitability and operating performance of our property portfolio. However, our use of the terms NOI, Cash NOI,

Pro-Rata

Cash NOI and Same-Store NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing these amounts.

NOI, Cash NOI,

Pro-Rata

Cash NOI and Same-Store NOI are not equivalent to our net income (loss) as determined under

GAAP and may not be a useful measure in measuring operational income or cash flows. Furthermore, NOI, Cash NOI,

Pro-Rata

Cash NOI and Same-Store NOI should not be considered as alternatives to net income... (truncated)ation of our liquidity. NOI, Cash NOI,

Pro-Rata

Cash NOI and Same-Store NOI should not be construed to be more relevant or accurate than the GAAP methodology in calculating net income (loss). NOI, Cash NOI,

Pro-Rata

Cash NOI and Same-Store NOI should be reviewed in conjunction with other measurements as an indication of our performance.

About American Healthcare REIT, Inc.

American Healthcare REIT, Inc. (NYSE: AHR) is a real estate investment trust that acquires, owns and operates a diversified portfolio of clinical healthcare real estate, focusing primarily on senior housing communities, skilled nursing facilities, and outpatient medical buildings across the United States, and in the United Kingdom and the Isle of Man.

Page | 6

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · American Healthcare REIT earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.